Development of new indicators for the launch of a Japanese version of the NIH (3) : Analysis of entities conducting pharmaceutical R^|^amp;D activities

Abstract

For the sake of providing evidences that contribute to policy making or strategy planning in a Japanese version of the NIH and pharmaceutical companies,we tried an overview and future prospects of pharmaceutical industry based on new indicators. Focusing on the sizes and categories of the entities possessing pipelines, we analyzed who the key entity is in terms of drug R&D. Results show that the SMEs and ventures give strong advantage in the drug R&D in U. S.. On the other hand, the SMEs and ventures in Japan do not play a vital role like those in U. S. do.